Clinical Drug Investigation

, Volume 27, Issue 9, pp 591–604 | Cite as

Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease

A Review
Review Article


HMG-CoA reductase inhibitors (statins) are the drugs of first choice for treating hypercholesterolaemia in order to prevent or slow the progression of coronary heart disease (CHD). Statins generally reduce the risk of CHD morbidity or mortality by about 30%. Lovastatin is effective in lowering plasma total cholesterol and low-density lipoprotein cholesterol levels, and is widely prescribed for both the primary and secondary prevention of CHD. In the major AFCAPS/TexCAPS primary prevention study of 6605 middle-aged or elderly men and women without symptomatic cardiovascular disease and with only moderately elevated serum lipids, treatment with lovastatin 20–40mg once daily for a mean of 5.2 years significantly (p < 0.001) reduced the incidence of a first acute major cardiac event by 37% compared with placebo. In the smaller ACAPS study of 919 men and women who were asymptomatic for cardiovascular disease, but with evidence of early atherosclerosis, treatment with lovastatin for 3 years significantly (p = 0.001) slowed or reversed atherosclerosis compared with placebo, as measured by changes in the intimal-medial thickness of carotid arteries on B-mode ultrasound. Three randomised, controlled, secondary prevention trials have demonstrated that in patients with coronary artery disease, treatment with lovastatin 20–80 mg/day alone or in combination with colestipol for 2–2.5 years reduced the severity of stenosis and/or slowed or reversed the progression of atherosclerosis, as assessed by angiography. In the FATS study, the severity of stenosis after 2.5 years in recipients of lovastatin plus colestipol was reduced by 2.8% compared with placebo, while the frequency of lesion progression was halved and the frequency of lesion regression was tripled. Treatment with lovastatin for 2.2 years in the MARS study significantly reduced the mean percent diameter stenosis compared with placebo (p = 0.005) in patients with more severe stenosis, and also significantly (p = 0.002) reduced the mean global change score (indicating less progression). In the CCAIT study, lovastatin therapy for 2 years significantly improved coronary change scores (p < 0.01) and significantly reduced the incidence of new lesions (p = 0.001) compared with placebo. Across the primary and secondary prevention studies, lovastatin was shown to be similarly effective in women, the elderly, smokers and in subjects with hypertension, hypercholesterolaemia or type 2 diabetes mellitus. Therefore, the available data demonstrate that lovastatin provides significant lipid-modifying efficacy, slows progression or causes regression of atherosclerosis, and protects against acute cardiac events, in both those with and those without symptomatic CHD.


Simvastatin Atorvastatin Lovastatin Rosuvastatin Fluvastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Preparation of this manuscript was supported by Recordati. The authors would like to thank Wolters Kluwer Health for editorial assistance in the production of this manuscript.

The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143-421Google Scholar
  2. 2.
    Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000; 320(7236): 705–8CrossRefGoogle Scholar
  3. 3.
    Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000; 139(4): 577–83PubMedCrossRefGoogle Scholar
  4. 4.
    Klotz U. Pharmacological comparison of the statins. Arzneimittelforschung 2003; 53(9): 605–11PubMedGoogle Scholar
  5. 5.
    Farnier M. The hyperlipidemias: role of various statins [in French]. Presse Med 1999; 28(36): 2002–10PubMedGoogle Scholar
  6. 6.
    Singh BK, Mehta JL. Management of dyslipidemia in the primary prevention of coronary heart disease. Curr Opin Cardiol 2002; 17(5): 503–11PubMedCrossRefGoogle Scholar
  7. 7.
    Gotto Jr AM, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001; 12(4): 391–4CrossRefGoogle Scholar
  8. 8.
    Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19(9): 683–9PubMedCrossRefGoogle Scholar
  9. 9.
    Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med 1993; 153(9): 1079–87CrossRefGoogle Scholar
  10. 10.
    Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med 1991; 91(1B): 18S–24SPubMedCrossRefGoogle Scholar
  11. 11.
    Swislocki AL, Lin K, Cogburn D, et al. Postmarketing analysis of lovastatin use in the VA Northern California System of Clinics: a retrospective, computer-based study. Am J Manag Care 1997; 3(10): 1537–45PubMedGoogle Scholar
  12. 12.
    Farnier M, Davignon J. Current and future treatment of hyper-lipidemia: the role of statins. Am J Cardiol 1998; 82(4B): 3J–10JPubMedCrossRefGoogle Scholar
  13. 13.
    Rossouw J. Workshop on stabilization and regression of atherosclerosis. Newspaper Cardiol 1991; Aug 1Google Scholar
  14. 14.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–22PubMedCrossRefGoogle Scholar
  15. 15.
    Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90(4): 1679–87PubMedCrossRefGoogle Scholar
  16. 16.
    Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151(1): 43–9PubMedCrossRefGoogle Scholar
  17. 17.
    Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323(19): 1289–98PubMedCrossRefGoogle Scholar
  18. 18.
    Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119(10): 969–76PubMedGoogle Scholar
  19. 19.
    Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89(3): 959–68PubMedCrossRefGoogle Scholar
  20. 20.
    Waters D, Higginson L, Gladstone P, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995; 92(9): 2404–10PubMedCrossRefGoogle Scholar
  21. 21.
    Waters D, Lesperance J, Gladstone P, et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. CCAIT Study Group. Circulation 1996; 94(4): 614–21PubMedCrossRefGoogle Scholar
  22. 22.
    Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001; 10(10): 971–81PubMedCrossRefGoogle Scholar
  23. 23.
    Gotto Jr AM, Boccuzzi SJ, Cook JR, et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. Am J Cardiol 2000; 86(11): 1176–81PubMedCrossRefGoogle Scholar
  24. 24.
    Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med 1997; 337: 356]. N Engl J Med 1997; 336: 973–9PubMedCrossRefGoogle Scholar
  25. 25.
    Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43PubMedCrossRefGoogle Scholar
  26. 26.
    Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–42PubMedCrossRefGoogle Scholar
  27. 27.
    Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199–204PubMedCrossRefGoogle Scholar
  28. 28.
    Ridker PM, Stampfer MJ, Nifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–5PubMedCrossRefGoogle Scholar
  29. 29.
    Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230–5PubMedCrossRefGoogle Scholar
  30. 30.
    Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191–3PubMedCrossRefGoogle Scholar
  31. 31.
    Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344(26): 1959–65PubMedCrossRefGoogle Scholar
  32. 32.
    Probstfield JL, Margitic SE, Byington RP, et al. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol 1995; 76(9): 47C–53CPubMedCrossRefGoogle Scholar
  33. 33.
    Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol 1990; 66(8): 44B–55BPubMedCrossRefGoogle Scholar
  34. 34.
    Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124(6): 548–56PubMedGoogle Scholar
  35. 35.
    Hodis HN, Mack WJ, Azen SP, et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90(1): 42–9PubMedCrossRefGoogle Scholar
  36. 36.
    Pyorala K, Laakso M, Uusihpa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463–524PubMedCrossRefGoogle Scholar
  37. 37.
    Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318(2): 81–6PubMedCrossRefGoogle Scholar
  38. 38.
    Garg A, Grundy SM. Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin. Am J Cardiol 1988; 62(15): 44J–9JPubMedCrossRefGoogle Scholar
  39. 39.
    Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91(1B): 25S–30SPubMedCrossRefGoogle Scholar
  40. 40.
    Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81(5): 582–7PubMedCrossRefGoogle Scholar
  41. 41.
    Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996; 125(12): 990–1000PubMedGoogle Scholar
  42. 42.
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326(7404): 1423PubMedCrossRefGoogle Scholar
  43. 43.
    Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32(3): 665–72PubMedCrossRefGoogle Scholar
  44. 44.
    Zhou Z, Rahme E, Abrahamowicz M, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005; 172(9): 1187–94PubMedCrossRefGoogle Scholar
  45. 45.
    Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28(1): 26–35PubMedCrossRefGoogle Scholar
  46. 46.
    Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEX-CAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87(9): 1074–9PubMedCrossRefGoogle Scholar
  47. 47.
    Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990; 50: 65–78PubMedCrossRefGoogle Scholar
  48. 48.
    Laties AM, Shear CL, Lippa EA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol 1991; 67(6): 447–53PubMedCrossRefGoogle Scholar
  49. 49.
    Chylack Jr LT, Mantell G, Wolfe JK, et al. Lovastatin and the human lens: results of a two year study. The MSDRL Study Group. Optom Vis Sci 1993; 70(11): 937–43PubMedCrossRefGoogle Scholar
  50. 50.
    Pedersen TR. Statin trials and goals of cholesterol-lowering therapy after AMI. Am Heart J 1999; 138 (2 Pt 2): S177–82PubMedCrossRefGoogle Scholar
  51. 51.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504PubMedCrossRefGoogle Scholar
  52. 52.
    LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425–35PubMedCrossRefGoogle Scholar
  53. 53.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291(9): 1071–80PubMedCrossRefGoogle Scholar
  54. 54.
    Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295(13): 1556–65PubMedCrossRefGoogle Scholar
  55. 55.
    Crouse 3rd JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297(12): 1344–53PubMedCrossRefGoogle Scholar
  56. 56.
    Shovman O, Levy Y, Gilburd B, et al. Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002; 25(3): 271–85PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Divisione di Cardiologia Riabilitativa, Presidio Ospedaliero di PassiranaA.O. ‘G. Salvini’ Garbagnate Milanese (MI)MilanItaly
  2. 2.S.S. Unita’ di Cure Intensive CardiologicheDipartimento Cardiologico ‘A. De Gasperis’, A.O. Ospedale Niguarda Ca’ GrandaMilanItaly

Personalised recommendations